Want to see RLAY full AI Analyst Report?
Total Valuation
Relay Therapeutics has a market cap or net worth of $4.26B. The enterprise value is $2.92K.
Market Cap$4.26B
Enterprise Value$2.92K
Share Statistics
Relay Therapeutics has 219,141,630 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding219,141,630
Owned by Insiders1.59%
Owned by Institutions60.01%
Financial Efficiency
Relay Therapeutics’s return on equity (ROE) is -0.49 and return on invested capital (ROIC) is -50.50%.
Return on Equity (ROE)-0.49
Return on Assets (ROA)-0.44
Return on Invested Capital (ROIC)-50.50%
Return on Capital Employed (ROCE)-0.51
Revenue Per Employee76.01K
Profits Per Employee-1.37M
Employee Count202
Asset Turnover0.02
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Relay Therapeutics is ―. Relay Therapeutics’s PEG ratio is 0.17.
PE Ratio―
PS Ratio94.54
PB Ratio2.56
Price to Fair Value2.56
Price to FCF-6.15
Price to Operating Cash Flow-18.58
PEG Ratio0.17
Income Statement
In the last 12 months, Relay Therapeutics had revenue of 15.36M and earned -276.48M in profits. Earnings per share was -1.61.
Revenue15.36M
Gross Profit11.80M
Operating Income-302.74M
Pretax Income-276.48M
Net Income-276.48M
EBITDA-272.92M
Earnings Per Share (EPS)-1.61
Cash Flow
In the last 12 months, operating cash flow was -212.21M and capital expenditures 0.00, giving a free cash flow of -212.21M billion.
Operating Cash Flow-212.21M
Free Cash Flow-212.21M
Free Cash Flow per Share-0.97
Dividends & Yields
Relay Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.10
52-Week Price Change453.85%
50-Day Moving Average18.75
200-Day Moving Average12.33
Relative Strength Index (RSI)49.76
Average Volume (3m)3.71M
Important Dates
Relay Therapeutics upcoming earnings date is Nov 11, 2026, Before Open (Confirmed).
Last Earnings DateAug 6, 2026
Next Earnings DateNov 11, 2026
Ex-Dividend Date―
Financial Position
Relay Therapeutics as a current ratio of 22.61, with Debt / Equity ratio of 3.44%
Current Ratio22.61
Quick Ratio22.61
Debt to Market Cap0.00
Net Debt to EBITDA0.19
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Relay Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Relay Therapeutics EV to EBITDA ratio is -5.13, with an EV/FCF ratio of -5.94.
EV to Sales91.18
EV to EBITDA-5.13
EV to Free Cash Flow-5.94
EV to Operating Cash Flow-5.95
Balance Sheet
Relay Therapeutics has $910.93M in cash and marketable securities with $30.66M in debt, giving a net cash position of $880.28M billion.
Cash & Marketable Securities$910.93M
Total Debt$30.66M
Net Cash$880.28M
Net Cash Per Share$4.02
Tangible Book Value Per Share$3.30
Margins
Gross margin is -566.59%, with operating margin of -1971.59%, and net profit margin of -1800.58%.
Gross Margin-566.59%
Operating Margin-1971.59%
Pretax Margin-1800.58%
Net Profit Margin-1800.58%
EBITDA Margin-1777.41%
EBIT Margin-1800.58%
Analyst Forecast
The average price target for Relay Therapeutics is $27.44, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$27.44
Price Target Upside48.83% Upside
Analyst ConsensusStrong Buy
Analyst Count10
Revenue Growth Forecast23.86%
EPS Growth Forecast19.60%